title: 24-h Intraocular pressure control with evening-dosed travoprost/timolol, compared with latanoprost/timolol, fixed combinations in exfoliative glaucoma.
abstract: OBJECTIVE
  To evaluate 24-h efficacy of travoprost/timolol fixed combination (TTFC) vslatanoprost/timolol fixed combination (LTFC) in exfoliative glaucoma (XFG).
  
  
  METHODS
  A prospective, single-masked, crossover, active-controlled, randomized 24-h comparison.
  
  
  METHODS
  After up to a 6-week medicine-free period, XFG patients were randomized to either TTFC or LTFC for 3 months, dosed each evening, and then changed to the opposite treatment for another 3 months. At the end of the washout, and both treatment periods, a 24-h intraocular pressure (IOP) curve was measured.
  
  
  RESULTS
  In total, 40 patients completed the study. The TTFC group showed a lower mean absolute 24-h IOP (18.7±2.6 vs 19.6±2.6 mm Hg, P<0.001), maximum IOP (20.5±2.6 vs 21.5±2.6 mm Hg, P<0.001) and 24-h IOP range (3.4±1.3 vs 4.1±1.6 mm Hg, P=0.01). At individual time points, TTFC showed reduced IOPs compared with LTFC, after a Bonferroni correction, at 1000, 1800, and 2200 hours (P≤0.04). No statistical differences existed at hours: 0600, 1400, and 0200 (P≥0.05) and for the minimum IOP (P=0.09).
  
  
  CONCLUSIONS
  This study suggests that evening-dosed TTFC may provide greater 24-h IOP reduction, primarily at the 1800 hours time point, compared with LTFC in XFG.
authors.affiliation: Glaucoma Unit, Department of Ophthalmology, First University, Thessaloniki, Greece.
authors.forename: A G P
authors.initials: AG
authors.lastname: Konstas
authors.forename: D G
authors.initials: DG
authors.lastname: Mikropoulos
authors.forename: T A
authors.initials: TA
authors.lastname: Embeslidis
authors.forename: A T
authors.initials: AT
authors.lastname: Dimopoulos
authors.forename: A
authors.initials: A
authors.lastname: Papanastasiou
authors.forename: A-B
authors.initials: AB
authors.lastname: Haidich
authors.forename: W C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use*; D003008:Cloprostenol / Q000031:analogs & derivatives* / Q000627:therapeutic use; D018592:Cross-Over Studies; D004334:Drug Administration Schedule; D004359:Drug Therapy, Combination; D017889:Exfoliation Syndrome / Q000188:drug therapy*; D005260:Female; D005901:Glaucoma / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D000077338:Latanoprost; D008297:Male; D008875:Middle Aged; D011446:Prospective Studies; D011461:Prostaglandins F, Synthetic / Q000627:therapeutic use*; D016037:Single-Blind Method; D013997:Time Factors; D013999:Timolol / Q000627:therapeutic use*; D000069557:Travoprost
chemical_list: D000959:Antihypertensive Agents; D011461:Prostaglandins F, Synthetic; D003008:Cloprostenol; D000077338:Latanoprost; D013999:Timolol; D000069557:Travoprost